Frankfurter Institut Fuer Klinische Krebsforschung IKF GmbH — Sponsor Intelligence | 25 EU Trials

Filter these 25 trials by condition, phase, country and more.

Open in Search →

25 Registered trials

11 Recruiting

12 Completed trials

5 Countries active

45 Unique IMPs

100% Results reported

Phase II

Phase III: 2 Phase II/III: 2 Phase II: 18 Phase I/II: 1 Phase I (Other): 2

Oversight events:

3 temporary halts across 2 trials

View oversight register →

100%

12 of 12 completed trials have published summary results (EU CTR Article 37 — 12-month obligation).

View full Transparency Scoreboard →

Top indications

Gastrooesophageal cancer 4 Non-small cell lung cancer 2 HER2 positive gastric cancer 2 Hepatocellular carcinoma 1 Non-small cell lung cancer stage IIIA 1 B-cell lymphoma 1 Diffuse large B-cell lymphoma recurrent 1 Hepatic cancer 1 Non-small cell lung cancer stage III 1 Cholangiocarcinoma 1 Oesophageal adenocarcinoma 1 Biliary tract operation 1

Top IMPs

FLUOROURACIL 6 CALCIUM FOLINATE PENTAHYDRATE 5 OXALIPLATIN 5 DURVALUMAB 4 DOCETAXEL 3 ATEZOLIZUMAB 2 BEVACIZUMAB 2 CEMIPLIMAB 2 GLOFITAMAB 2 OBINUTUZUMAB 2 PEMBROLIZUMAB 2 TISLELIZUMAB 2

All trials

25 total

Double-T - Improving outcomes in high-risk 2nd line relapsed/refractory Large B-Cell Lymphoma patients eligible for CAR-T-cell therapy with … Pending

2025-523806-34-00 Phase II 1 country AXICABTAGENE CILOLEUCEL; GLOFITAMAB; LISOCABTAGENE MARALEUCEL; OBINUTUZUMAB
Bemarituzumab in patients with FGFR2b-positive advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction, who failed… Recruiting

2024-512484-31-00 Phase II 2 countries BEMARITUZUMAB; TRIFLURIDINE, TIPIRACIL HYDROCHLORIDE
NeoMatryx - Neoadjuvant Merkel cell carcinoma therapy (Tx) with the PD-1 inhibitor Cemiplimab – A randomized, double-blind, placebo-controll… Recruiting

2025-522091-84-00 Phase II 1 country CEMIPLIMAB
ZANGEA – Phase II Study of Zanidatamab in Combination with Pembrolizumab and Chemotherapy in HER2 and PD-L1 Positive Metastatic Gastroesopha… Recruiting

2025-522718-22-00 Phase II 1 country ZANIDATAMAB
NeoTISLEGA - A phase Ib trial evaluating the safety and activity of neoadjuvant combination of tislelizumab plus FLOT for resectable esophag… Recruiting

2024-519993-38-00 Phase I (Other) 1 country
FUTURE Recruiting

2024-517573-24-00 Phase II 1 country CALCIUM FOLINATE PENTAHYDRATE; FLUOROURACIL; FUTIBATINIB; OXALIPLATIN; TISLELIZU…
DEPECA-1 – DEfeating PEnile CAncer 1 – A Phase II study to evaluate a first-line systemic therapy with enfortumab vedotin plus avelumab for … Recruiting

2025-521644-37-00 Phase II 1 country AVELUMAB; ENFORTUMAB VEDOTIN
adIVO Recruiting

2024-520219-42-00 Phase II/III 1 country IVOSIDENIB
– IKF/AIO-QUINTIS – A Randomized Phase II Trial Evaluating Fruquintinib in Combination with Tislelizumab in Microsatellite Stable / Profici… Recruiting

2024-519929-38-00 Phase II 2 countries BEVACIZUMAB; FRUQUINTINIB; TISLELIZUMAB; TRIFLURIDINE, TIPIRACIL HYDROCHLORIDE
Evaluation of efficacy and safety of Cemiplimab as first line treatment for advanced basal cell carcinoma (CEMI-first) - An open label, sing… Recruiting

2024-517647-31-00 Phase II 1 country CEMIPLIMAB
The ABC-HCC Trial: A Phase IIIb, randomized, multicenter, open-label trial of Atezolizumab plus Bevacizumab versus transarterial Chemoemboli… Recruiting

2024-512953-26-00 Phase III 5 countries ATEZOLIZUMAB; BEVACIZUMAB
IMMUWIN - A Phase II study of immunotherapy with durvalumab (MEDI4736) and tremelimumab in combination with Y-90 SIRT for intermediate stage… Recruiting

2024-513950-32-00 Phase II 1 country DURVALUMAB
The PRESTO Trial - Organ preservation with durvalumab-based immunotherapy in combination with chemoradiation as definitive therapy for early… Ended

2024-512980-29-00 Phase II 1 country CALCIUM FOLINATE PENTAHYDRATE; DOCETAXEL; DURVALUMAB; FLUOROURACIL; OXALIPLATIN
A prospective multicenter phase 2 study of the chemotherapy-light combination of intravenous rituximab with the antibody-drug conjugate pol… Ended

2024-513949-37-00 Phase II 2 countries GLOFITAMAB; OBINUTUZUMAB; POLATUZUMAB VEDOTIN; RITUXIMAB
Pembrolizumab and trastuzumab in combination with FLOT in the perioperative treatment of HER2-positive, localized esophagogastric adenocarci… Ended

2024-513610-34-00 Phase II 1 country DISODIUM FOLINATE; DOCETAXEL; FLUOROURACIL; OXALIPLATIN; PEMBROLIZUMAB; TRASTUZU…
ABP - Advancing Brigatinib Properties in anaplastic lymphoma kinase positive nonsmall cell lung cancer (ALK+ NSCLC) patients by deep phenoty… Ended

2024-513947-94-00 Phase II 1 country BRIGATINIB; CERITINIB
DANTE / FLOT8 A randomized, open-label Phase II/III efficacy and safety study of atezolizumab in combination with FLOT versus FLOT alone in … Ended

2024-514945-12-00 Phase II/III 1 country ATEZOLIZUMAB; CALCIUM FOLINATE PENTAHYDRATE; DOCETAXEL; FLUOROURACIL; OXALIPLATI…
„INSIGHT“ An explorative, open-labeled, phase I trial to evaluate feasibility and safety of eftilagimod alpha (IMP321, a LAG-3Ig fusion prot… Ended

2024-516026-56-00 Phase I (Other) 1 country
NeoART – A phase Ib/II platform trial evaluating the safety and activity of neoadjuvant trastuzumab-deruxtecan containing combination therap… Halted

2024-518841-12-00 Phase I/II 2 countries CALCIUM FOLINATE PENTAHYDRATE; FLUOROURACIL; OXALIPLATIN; TRASTUZUMAB DERUXTECAN
PEARLDIFER - A Phase II study of pemigatinib after curative local therapy in locally advanced intrahepatic cholangiocarcinoma (iCCA) harbori… Ended

2024-512018-16-00 Phase II 1 country PEMIGATINIB
Phase II Study of Fedratinib and Nivolumab Combination in Patients with Myelofibrosis and Resistance or Suboptimal Response to JAK-inhibitor… Ended

2024-513953-64-00 Phase II 1 country FEDRATINIB; NIVOLUMAB
ADJUBIL - A Phase II study of immunotherapy with durvalumab and tremelimumab in combination with capecitabine or without capecitabine in ADJ… Ended

2024-511847-24-00 Phase II 1 country DURVALUMAB
SOLARIS – A phase-II open-label study of pembrolizumab and lenvatinib in patients with advanced stage hepatocellular carcinoma who are refra… Ended

2024-515731-29-00 Phase II 1 country LENVATINIB; PEMBROLIZUMAB
Thoracic Radiotherapy plus Durvalumab in Elderly and/or frail NSCLC stage III patients unfit for chemotherapy - Employing optimized (hypofra… Ended

2024-513948-28-00 Phase II 1 country DURVALUMAB

Showing 1–24 of 25 trials

← All sponsors A–Z